Many of the prescription medicines on the market today were developed with the assistance of Covance Inc., one of the world’s largest drug-development services companies. Covance helps pharmaceutical and biotechnology companies by providing testing services including preclinical investigations; by designing and carrying out human clinical trials; and by determining the safety and effectiveness of drugs through post-marketing studies. Covance also conducts toxicology studies and biostatistical analyses and offers testing services for the chemical, agrochemical and food industries.
The company was born of a Corning Inc. move into laboratory and clinical services during the 1980s, when the glass maker acquired a number of drug-development companies. In 1997, it spun off these businesses into a single publicly traded, independent entity Covance. As of last year, the company’s revenues of more than $2 billion earned for it the No. 858 position on the Fortune 1,000. Covance maintains headquarters in Princeton, N.J., and has more than 11,000 employees in 60 countries.
LEGAL TEAM AND OUTSIDE COUNSEL
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
